“If the ICS data is positive, we would have increased confidence to start looking at CVac to treat other cancer types outside of ovarian cancer.”
Considering that this data isn't event based (PFS/OS), can we expect Prima to reveal the level of T-cell stimulation before the release phase 2b interim results? The time frame to measure an immune response will be much shorter than survival benefit.
Positive data could add a healthy spike to the SP before interim results. Just as today's announcements were a surprise, there may be more positive ones we aren't expecting, too. Just a thought.
I like this bit: "But we will keep everyone very well informed in advance of our presentation of results."
Not much wriggle room in re-interpreting that sentence.
I like this Lehman guy already
PRR Price at posting:
10.6¢ Sentiment: LT Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)